CRISCuris, Inc.

$14M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+38.9% YoY

Gross Profit

$2M94.9% margin

Operating Income

-$14M-592.1% margin

Net Income

-$15M-632.4% margin

EPS (Diluted)

$-10.55

QoQ Revenue Growth

+18.6%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$82M

Total Liabilities

$52M

Stockholders' Equity

$30M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+38.9%
Gross Profit	$2M	$2M	+39.3%
Operating Income	-$14M	-$28M	+47.9%
Net Income	-$15M	-$28M	+45.5%

Revenue Segments

Drug Development Royalty

$100,000100%

CRIS Q3 2017 Earnings — Curis, Inc. Revenue & Financial Results | Market Cap Arena